Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul-Sep;43(3):156-166.
Epub 2023 Sep 14.

Long-term Effects of Gastric Acid Prophylaxis in Kidney Transplant Recipients

Halil Yazici  1 , Ozgur Akin Oto  1 , Safak Mirioglu  1   2 , Ahmet Burak Dirim  1 , Erol Demir  1 , Omer Uludag  1 , Omer Faruk Akardere  1 , Yasar Caliskan  1   3 , Krista L Lentine  3
Affiliations

Long-term Effects of Gastric Acid Prophylaxis in Kidney Transplant Recipients

Halil Yazici et al. Rev Nefrol Dial Transpl. 2023 Jul-Sep.

Abstract

Objectives: Prophylactic acid suppression with proton pump inhibitors or H2 receptor antagonists is often administered after kidney transplantation. The Association of proton pump inhibitors or H2 receptor antagonists with acute rejection, hypomagnesemia, and graft loss in kidney transplant recipients is not well established.

Material and methods: We performed a retrospective cohort study of 302 kidney transplant recipients at one center (57% male; mean age 35.5±11.2 years) with more than 6 months post-transplant follow-up. Recipients were grouped according to gastric acid prophylaxis: only proton pump inhibitors (n=179), only H2 receptor antagonists (n=42), proton pump inhibitors and H2 receptor antagonists (n=55), and nonusers (n=26). The primary outcome was biopsy-proven acute rejection. Graft loss and hypomagnesemia were defined as secondary outcomes.

Results: Nonusers were younger and mostly under steroid-free immunosuppression compared to other study groups (p=0.030 and p=0.009, respectively). The primary outcome was similar across study groups (p=0.266). Kaplan-Meier analyses also demonstrated similar 10-year graft survival rates: 95.5% for proton pump inhibitors, 97.6% for H2 receptor antagonists, 100% for proton pump inhibitors/H2 receptor antagonists, and 96.2% for nonusers (p=0.275).

Conclusions: The use of proton pump inhibitors is not associated with acute rejection or graft loss but may cause mild hypomagnesemia in kidney transplant recipients.

Keywords: H2 receptor antagonists; acute rejection; hypomagnesemia; kidney transplantation; proton pump inhibitors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Ten-year graft survival rates were 95.5% in PPI, 97.6% in H2RA, 100% in PPI/H2RA, and 96.2% in nonuser groups (p=0.275 with log-rank test) (H2RA: H2 receptor antagonist, PPI: proton pump inhibitor)
See this image and copyright information in PMC

References

    1. Hess M, Hoenderop J, Bindels R, Drenth J. Systematic review: hypomagnesaemia induced by proton pump inhibition. Alimentary pharmacology & therapeutics. 2012;36(5):405–413. - PubMed
    1. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Renal failure. 2015;37(7):1237–1241. - PubMed
    1. Hoorn EJ, van der Hoek J, Rob A, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor–induced hypomagnesemia. American journal of kidney diseases. 2010;56(1):112–116. - PubMed
    1. Cundy T, Dissanayake A. Severe hypomagnesaemia in long‐term users of proton‐pump inhibitors. Clinical endocrinology. 2008;69(2):338–341. - PubMed
    1. Van Ende C, Van Laecke S, Marechal C, et al. Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. Journal of nephrology. 2014;27(6):707–711. - PubMed

LinkOut - more resources